Seven Fleet Capital Management LP
MOUNTAIN VIEW, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$511.7M2026 Q3
Positions85
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.68.9%
What Changed This Quarter?
Top Holdings
CGON
CG Oncology
26.1%
TNGX
Tango Therapeutics
10.9%
RVMD
Revolution Medicines
10.6%
PHVS
Pharvaris N.V.
4.3%
ENTX
Entera Bio
3.9%
LQDA
Liquidia
3.5%
AVBP
ArriVent BioPharma
2.7%
ELVN
Enliven Therapeutics
2.3%
New / Increased
20 new · 27 increased
DMRANEW
Damora Therapeutics
1.2%
IMUXNEW
Immunic
0.7%
UTHRNEW
United Therapeutics
0.3%
HRMYNEW
Harmony Biosciences Hldgs
0.3%
Tcgx Acquisit…NEW
TCGX Acquisition
0.2%
ENTX
Entera Bio
3.9%
+3486.4%
LQDA
Liquidia
3.5%
+132.4%
AVBP
Arrivent Biopharma
2.7%
+83.0%
Reduced / Exited
30 reduced · 31 sold out
TNGX
Tango Therapeutics
10.9%
-30.8%
TARS
Tarsus Pharmaceuticals
0.7%
-58.5%
ELVN
Enliven Therapeutics
2.3%
-28.3%
CYTK
Cytokinetics
0.7%
-54.5%
COGT
Cogent Biosciences
0.1%
-86.9%
MIRMEXIT
Mirum Pharmaceuticals
2.1%
Damora Therap…EXIT
Damora Therapeutics
1.2%
MDGLEXIT
Madrigal Pharmaceuticals
0.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.